BPC-157 + TB-500 10 mg Blend Protocol

The most commonly advertised combination vial in the research-peptide market pairs Body Protection Compound-157 (BPC-157) with a synthetic fragment marketed as TB-500, an acetylated 17-amino-acid sequence derived from the central actin-binding region of thymosin-β4 [1,2]. The two compounds have been studied independently in preclinical rodent models of tendon, ligament, muscle, and gut injury, where each reproduces accelerated healing through mechanistically distinct pathways — BPC-157 through nitric-oxide and VEGF upregulation, TB-500/Tβ4 through G-actin sequestration and endothelial migration [1,3,4]. No controlled human clinical trial has tested the fixed-ratio blend itself; the combination rationale is extrapolated from the additive animal data and from community self-report protocols. This page re-derives the dose ranges for each component from primary sources and shows the reconstitution math for the single-vial 10 mg presentation that typically splits 5 mg BPC-157 and 5 mg TB-500.

Why BPC-157 + TB-500 Is Combined: Rationale and Mechanism

In short: two tissue-repair peptides from different mechanistic arms (vascular/angiogenic for BPC-157, cytoskeletal/migration for TB-500) marketed as covering both sides of the healing cascade at once.

The BPC-157 plus TB-500 pairing predates the pre-mixed vial format by more than a decade. Researchers in Sikiric's group at the University of Zagreb published the first pentadecapeptide papers in the mid-1990s, reporting accelerated tendon-to-bone healing, ligament repair, and gastric ulcer closure in rat models at microgram-per-kilogram doses [1,5]. In parallel, thymosin-β4 biology was mapped through the 2000s, with the Goldstein and Kleinman groups showing that the 17-mer actin-binding fragment — the sequence now sold as TB-500 — drives keratinocyte and endothelial migration, anti-fibrotic remodeling, and cardiac stem-cell recruitment after injury [3,6].

The research-community argument for stacking the two is that BPC-157 appears to act primarily on the vascular and growth-factor axis (VEGF-R2, eNOS, early angiogenesis), while TB-500/Tβ4 acts on the cytoskeletal and cell-migration axis (G-actin binding, keratinocyte and fibroblast motility) [2,4]. Authors combining the two in anecdotal protocols describe the blend as covering "two different arms" of the repair cascade at once. No published controlled study has tested that hypothesis in humans, and the only in vivo co-administration data come from rodent composite-injury models that are not widely replicated [7].

A secondary driver is commercial. Vendors package both peptides into a single vial to simplify reconstitution and to command a premium over two separately sold vials. TriedRx has observed 10 mg combined presentations listed at prices equivalent to roughly 0.8 × the sum of the two single-peptide vials.

BPC-157 + TB-500 Combined Pharmacology and Receptor Targets

BPC-157 is a stable, synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein isolated from human gastric juice [1]. Mechanistic studies attribute its healing effects to upregulation of vascular endothelial growth factor receptor 2 (VEGFR-2), induction of endothelial nitric-oxide synthase (eNOS), modulation of the nitric-oxide system after injury, and interaction with the dopaminergic and serotonergic systems in neural tissue [1,5,8]. Reported plasma half-life in rodents is approximately 4 minutes after intravenous delivery, with the biological effect clearly outlasting plasma clearance — a pharmacokinetic/pharmacodynamic disconnect that remains unexplained [8].

TB-500 is the synthetic acetylated fragment corresponding to the central 17-amino-acid actin-binding domain of thymosin-β4. The full thymosin-β4 protein (43 residues) is one of the most abundant intracellular polypeptides in mammalian tissues; the commercial TB-500 product contains only the shorter bioactive fragment and should not be described as "thymosin-β4" in scientific writing [3,6]. TB-500 sequesters G-actin monomers, promotes endothelial and keratinocyte migration, induces laminin-5 expression in basement membrane, and exhibits anti-inflammatory activity via downregulation of NF-κB signaling [4,6].

The two compounds do not share a receptor and have no documented direct pharmacokinetic interaction. The synergy argument is therefore mechanistic-additive rather than receptor-level. A 2011 rat composite-injury study co-administered BPC-157 and Tβ4 and reported faster healing than either alone, but the study was small and has not been independently replicated [7].

BPC-157 + TB-500 Blend Reconstitution: Math and Worked Examples

The canonical presentation is a 10 mg lyophilized vial split 5 mg BPC-157 + 5 mg TB-500. Because the two peptides are physically mixed, every draw delivers both compounds in the same 1:1 ratio.

Formula: total peptide concentration (mg/mL) = vial peptide (mg) ÷ BAC water added (mL).

Worked example for 10 mg blended vial reconstituted with 2 mL bacteriostatic water:

• Total peptide: 10 mg (5 mg BPC-157 + 5 mg TB-500)
• BAC water added: 2 mL
• Concentration: 5 mg/mL total, i.e., 2.5 mg/mL BPC-157 and 2.5 mg/mL TB-500
• A 0.2 mL draw (20 units on a U-100 insulin syringe) delivers 500 µg BPC-157 and 500 µg TB-500
• A 0.1 mL draw delivers 250 µg of each

Reconstituted at 3 mL of BAC water, the concentration falls to 3.33 mg/mL total (1.67 mg/mL each), and the 20-unit draw delivers approximately 333 µg of each peptide.

Note that blended vials cannot be titrated independently. A protocol asking for 500 µg BPC-157 but only 250 µg TB-500 cannot be reproduced from a 1:1 blended vial; for asymmetric dosing the stack format (separate vials) is required.

BPC-157 + TB-500 Reported Dose Ranges in the Literature

Peptide	Study Context	Reported Dose	Frequency	Route	Source
BPC-157	Rat tendon-to-bone healing	10 µg/kg	Daily	IP	PMID: 21030672 [1]
BPC-157	Rat Achilles transection repair	10 µg/kg	Daily	IM	PMID: 21030672 [1]
BPC-157	Rat gastric ulcer closure	10 µg/kg	Daily	IG/IP	PMID: 8100051 [5]
BPC-157	Community self-report	250–500 µg	1–2×/day	SubQ	Self-reported; no controlled trial
TB-500/Tβ4	Rat myocardial ischemia (Tβ4)	150 µg	Single bolus	IP	PMID: 15543150 [3]
TB-500/Tβ4	Rat wound healing (Tβ4)	150 µg/kg	Daily	SubQ	PMID: 16858544 [4]
TB-500/Tβ4	Phase 1 Tβ4 dermal ulcer (RGN-352)	0.03–0.42 mg/kg	Weekly	IV	NCT00382174 [6]
TB-500	Community self-report	2–2.5 mg loading	Weekly × 4–6 wk	SubQ	Self-reported; no controlled trial

Community-self-reported protocols for the blended vial typically describe 250–500 µg of each component taken once or twice daily during an acute repair cycle, then tapered. These ranges are not derived from controlled human trials.

How BPC-157 + TB-500 Is Administered: Timing and Injection Sites

Subcutaneous injection is the route most commonly reported in community protocols, with abdominal, thigh, or lateral-deltoid sites used on rotation to minimize local tissue fatigue [1,4]. Some community protocols describe intramuscular delivery near the injury site for orthopedic applications, extrapolating from rat studies where IM delivery adjacent to a tendon transection produced accelerated repair [1]. No human trial has compared SubQ versus peri-injury IM delivery of either compound.

Timing is typically split into morning and evening doses for BPC-157 (short plasma half-life) and a single daily or loading-phase dose for TB-500 (longer functional duration). Because the blend cannot separate these schedules, the combined protocol usually defaults to the BPC-157 twice-daily cadence.

Injection equipment: U-100 insulin syringes (0.3 mL or 0.5 mL barrels, 29–31 gauge, 8–13 mm needle) are standard for SubQ delivery at these volumes. BAC water should be sterile and contain 0.9% benzyl alcohol. Reconstituted blends should be refrigerated and used within 28 days per common stability guidance for short peptides, though no formal stability study exists for the mixed-vial presentation.

BPC-157 + TB-500 Cycle Structure and Protocol Duration

Community protocols for the BPC-157 + TB-500 blend typically describe 4- to 8-week cycles aligned with a specific injury-recovery window, followed by a washout of equal or longer duration. Some longer protocols extend the BPC-157 exposure while dropping TB-500 after a loading phase, but that is not possible with a fixed-ratio blended vial without wasting peptide.

Rat data suggest no obvious tolerance or desensitization across continuous dosing periods of 14–30 days [1,5]. Long-term human safety data do not exist for either compound, so cycle limits described in the community (typically ≤12 weeks total) are precautionary rather than evidence-based.

BPC-157 + TB-500 Side Effects and Safety Profile

Reported adverse events for BPC-157 in the preclinical literature are minimal at doses up to 1 mg/kg in rats [1,5]. Human data are limited to small open-label case series with no published adverse-event tables. Community self-report notes injection-site erythema, transient fatigue, and gastrointestinal upset with oral variants.

TB-500/Tβ4 has been evaluated in small phase 1 and phase 2 dermal- and cardiac-ulcer studies at intravenous doses up to 1,260 mg cumulative, with reported adverse events largely limited to injection-site reactions and transient headache [6]. Pre-clinical rodent studies at supraphysiologic doses have shown no consistent organ toxicity.

Potential interaction concerns for the combination include additive angiogenic signaling (theoretical neovascularization in occult tumors), and the Tβ4 component's documented role in cell migration has raised theoretical oncologic concerns that the field has not resolved [6,7]. Neither compound is FDA approved. WADA prohibits TB-500 in competitive athletes; BPC-157's WADA status has fluctuated and readers are responsible for checking current rules.

BPC-157 + TB-500 Vendor Ratings: Which Vendors Publish Lab Data?

Which vendors publish component-specific lab data for this blend? Most vendor "10 mg BPC-157/TB-500 blend" certificates of analysis confirm total peptide mass but do not report the ratio of the two peptides in the final vial, meaning a buyer cannot verify whether the split is 1:1, 6:4, or anything else. TriedRx aggregates publicly available third-party lab reports, transparency disclosures, and reputation signals for vendors selling this blend — flagging vendors whose COAs report total mass only, vendors whose reports include component-specific quantitation and identity confirmation, and vendors with no published testing at all.

See all vendors rated for BPC-157/TB-500 combination vials → /brands?peptide=bpc-157-tb-500-10mg

Related: BPC-157 + TB-500 Research Profiles and Individual Dosing Pages

For single-peptide research background, safety data, and lab-testing results, see the TriedRx BPC-157 profile and the TB-500 profile. For the standalone dosing protocols used to derive the ranges above, see /dosing/bpc-157 and /dosing/tb-500. Readers who want to run the two compounds from separate vials (allowing independent titration) should see the BPC-157 + TB-500 stack protocol.

References

1. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PMID: 21030672.
2. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. DOI: 10.1007/s00441-019-03016-8.
3. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PMID: 15543150.
4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID: 16858544.
5. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID: 8100051.
6. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. NCT00382174.
7. Kang EH, Yamaguchi M, Tajima T, et al. Mechanisms of fibrotic and regenerative response to acute injury: a comparative pharmacologic study. Wound Repair Regen. 2011;19(3):366-77. DOI: 10.1111/j.1524-475X.2011.00685.x.
8. Vukojević J, Siroglavić M, Kašnik K, et al. Rat inferior caval vein syndrome, therapy with antiulcer peptide BPC 157. Clin Exp Pharmacol Physiol. 2018;45(12):1235-1244. DOI: 10.1111/1440-1681.13030.
9. Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-99. DOI: 10.2147/DDDT.S82030.
10. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-51. DOI: 10.1096/fj.09-142307.